世卫组织发布GLP-1药物治疗肥胖指南，专家呼吁遵循医嘱科学减重

Core Viewpoint - The World Health Organization (WHO) has issued its first guidelines recommending the conditional use of GLP-1 (glucagon-like peptide-1) drugs for the treatment of obesity, emphasizing the need for a comprehensive management plan that includes healthy diet, regular exercise, and professional health guidance [1][3]. Group 1: Recommendations and Guidelines - GLP-1 drugs are recommended for long-term treatment of obesity in adults, excluding pregnant women, due to their significant efficacy in improving obesity and metabolic conditions, despite limited long-term safety data and high costs [1][3]. - The guidelines suggest providing enhanced behavioral interventions, including structured programs for healthy eating and physical activity, to improve treatment outcomes for adults receiving GLP-1 therapy [1][3]. Group 2: Obesity Statistics and Context - Obesity is a complex chronic disease that significantly contributes to non-communicable diseases such as cardiovascular diseases and type 2 diabetes, with the WHO projecting a global economic burden of $3 trillion by 2030 due to obesity [1]. - In China, the overweight rate among adults has reached 34.3%, with an obesity rate of 16.4%, highlighting the growing public health threat posed by obesity [3][4]. Group 3: Treatment and Management Insights - Lifestyle changes are fundamental for weight management, and while pharmacological treatments can be combined with lifestyle interventions, individual assessments are crucial for determining appropriate treatment plans [4][5]. - GLP-1 drugs exhibit dose-dependent effects, meaning different dosages can achieve varying weight loss results, and should only be used under medical supervision to ensure safety and effectiveness [5].